Label: ERYTHROMYCIN ointment

  • NDC Code(s): 0574-4024-35, 0574-4024-39, 0574-4024-50
  • Packager: Paddock Laboratories, LLC
  • Category: HUMAN PRESCRIPTION DRUG LABEL
  • DEA Schedule: None
  • Marketing Status: Abbreviated New Drug Application

Drug Label Information

Updated November 12, 2018

If you are a consumer or patient please visit this version.

  • DESCRIPTION:

    Erythromycin Ophthalmic Ointment belongs to the macrolide group of antibiotics. It is basic and readily forms a salt when combined with an acid. The base, as crystals or powder, is slightly soluble in water, moderately soluble in ether, and readily soluble in alcohol or chloroform. Erythromycin ((3R*,4S*,5S*,6R*,7R*,9R*,11R*,12R*,13S*,14R*)-4-[(2,6-dideoxy-3-C-methyl-3-0-methyl-α-L-ribo-hexopyranosyl)oxy]-14-ethyl-7,12,13-trihydroxy-3,5,7,9,11,13-hexamethyl-6-[[3,4,6-trideoxy-3-(dimethylamino)-ß-D-xylo-hexopyranosyl]oxy]oxacyclotetradecane-2,10-dione) is antibiotic produced from a strain of Streptomyces erythraeus. It has the following structural formula:

    Structure Image

    Each gram contains Erythromycin USP 5 mg in a sterile ophthalmic base of mineral oil and white petrolatum.

  • CLINICAL PHARMACOLOGY:

    Microbiology:

    Erythromycin inhibits protein synthesis without affecting nucleic acid synthesis. Erythromycin is usually active against the following organisms in vitro and in clinical infections:

    Streptococcus pyogenes (group A ß-hemolytic)

    Alpha-hemolytic streptococci (viridans group)

    Staphylococcus aureus, including penicillinase-producing strains (methicillin-resistant staphylococci are uniformly resistant to erythromycin)

    Streptococcus pneumonia

    Mycoplasma pneumoniae (Eaton Agent, PPLO)

    Haemophilus influenzae (not all strains of this organism are susceptible at the erythromycin concentrations ordinarily achieved)

    Treponema pallidum

    Corynebacterium diphtheriae

    Neisseria gonorrhoeae

    Chlamydia trachomatis

  • INDICATIONS AND USAGE:

    For the treatment of superficial ocular infections involving the conjunctiva and/or cornea caused by organisms susceptible to erythromycin.

    For prophylaxis of ophthalmia neonatorum due to N. gonorrhoeae or C. trachomatis. The effectiveness of erythromycin in the prevention of ophthalmia caused by penicillinase-producing N. gonorrheae is not established.

    For infants born to mothers with clinically apparent gonorrhea, intravenous or intramuscular injections of aqueous crystalline penicillin G should be given; a single dose of 50,000 units for term infants or 20,000 units for infants of low birth weight. Topical prophylaxis alone is inadequate for these infants.

  • CONTRAINDICATIONS:

    This drug is contraindicated in patients with a history of hypersensitivity to erythromycin.

  • PRECAUTIONS:

    General:

    The use of antimicrobial agents may be associated with the overgrowth of nonsusceptible organisms including fungi; in such a case, antibiotic administration should be stopped and appropriate measures taken.

    Information for Patients:

    Avoid contaminating the applicator tip with material from the eye, fingers, or other source.

    Carcinogenesis, Mutagenesis, Impairment of Fertility:

    Two year oral studies conducted in rats with erythromycin did not provide evidence of tumorigenicity. Mutagenicity studies have not been conducted.

    No evidence of impaired fertility that appeared related to erythromycin was reported in animal studies.

    Pregnancy:

    Teratogenic effects -

    Pregnancy Category B.

    Reproduction studies have been performed in rats, mice, and rabbits using erythromycin and its various salts and esters, at doses that were several multiples of the usual human dose. No evidence of harm to the fetus that appeared related to erythromycin was reported in these studies. There are, however, no adequate and well controlled studies in pregnant women. Because animal reproductive studies are not always predictive of human response, the erythromycins should be used during pregnancy only if clearly needed.

    Nursing Mothers:

    Caution should be exercised when erythromycin is administered to a nursing woman.

    Pediatric Use:

    See INDICATIONS AND USAGE and DOSAGE AND ADMINISTRATION.

  • ADVERSE REACTIONS:

    The most frequently reported adverse reactions are minor ocular irritations, redness, and hypersensitivity reactions.

    To report SUSPECTED ADVERSE REACTIONS, contact Perrigo at 1-866-634-9120 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

  • DOSAGE AND ADMINISTRATION:

    In the treatment of superficial ocular infections, a ribbon approximately 1 cm in length of Erythromycin Ophthalmic Ointment should be applied directly to the infected structure up to 6 times daily, depending on the severity of the infection. For prophylaxis of neonatal gonococcal or chlamydial conjunctivitis, a ribbon of ointment approximately 1 cm in length should be instilled into each lower conjunctival sac. The ointment should not be flushed from the eye following instillation. A new tube should be used for each infant.

  • HOW SUPPLIED

    Sterile Erythromycin Ophthalmic Ointment USP, 5 mg/g as follows:

    3.5 g (1/8 oz) tamper-evident tubes NDC 0574-4024-35

    24 x 3.5 g (1/8 oz) Hospital-Pak (for hospital use only) NDC 0574-4024-39

    Carton of fifty (50) Unit Dose 1 g tubes NDC 0574-4024-50

    Store at controlled room temperature 15°-30°C (59°-86°F). Avoid excessive heat.

    Protect from freezing.

  • SPL UNCLASSIFIED SECTION

    Manufactured For

    Perrigo®

    Minneapolis, MN 55427

    SW700 RC J1 Rev 09-13 A

    R1013

    Ini 0813

  • Package/Label Display Panel - Label

    Rx Only

    NDC 0574-4024-35

    Erythromycin Ophthalmic Ointment USP

    NET WT 3.5 g (1/8 OZ)

    STERILE

    Erythromycin Ophthalmic Label.jpg

    The following image is a placeholder representing the product identifier that is either affixed or imprinted on the drug package label during the packaging operation.

    C:\Users\sbrown\Pictures\serialization-template.jpg
  • Package/Label Display Panel - Carton

    Rx Only

    NDC 0574-4024-35

    Erythromycin Ophthalmic Ointment USP

    NET WT 3.5 g (1/8 OZ)

    STERILE

    5w7-rc-erythromycin-ophthalmic-ointment-35.jpg

    The following image is a placeholder representing the product identifier that is either affixed or imprinted on the drug package label during the packaging operation.

    serialization-template.jpg
  • Package/Label Display Panel-Hospital - Pak

    HOSPITAL-PAK

    Rx Only

    NDC 0574-4024-39

    Erythromycin Ophthalmic Ointment USP

    STERILE – 5 mg per Gram

    For Use in High Volume Neonatal Care

    HOSPITAL USE ONLY

    24 x 1/8 OZ (3.5 g)

    Each gram contains 5 mg of Erythromycin USP in a sterile ophthalmic base of mineral oil and white petrolatum.

    5w7-rc-erythromycin-ophthalmic-ointment-39.jpg

    The following image is a placeholder representing the product identifier that is either affixed or imprinted on the drug package label during the packaging operation.

    serialization-template.jpg
  • PACKAGE/LABEL PRINCIPAL DISPLAY PANEL - 50 Unit Doses

    Rx Only

    NDC 0574-4024-50

    Erythromycin Ophthalmic Ointment USP, 0.5% (5 mg/g)

    DO NOT REUSE. ONCE OPENED, DISCARD

    STERILE

    50 Unit Doses

    Sterile Ophthalmic Ointment weighing 1 gram each.

    5w7-rc-erythromycin-ophthalmic-ointment-50.jpg

    The following image is a placeholder representing the product identifier that is either affixed or imprinted on the drug package label during the packaging operation.

    serialization-template.jpg
  • INGREDIENTS AND APPEARANCE
    ERYTHROMYCIN 
    erythromycin ointment
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC:0574-4024
    Route of AdministrationOPHTHALMIC
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    ERYTHROMYCIN (UNII: 63937KV33D) (ERYTHROMYCIN - UNII:63937KV33D) ERYTHROMYCIN5 mg  in 1 g
    Inactive Ingredients
    Ingredient NameStrength
    PETROLATUM (UNII: 4T6H12BN9U)  
    MINERAL OIL (UNII: T5L8T28FGP)  
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC:0574-4024-351 in 1 CARTON05/08/2014
    13.5 g in 1 TUBE; Type 0: Not a Combination Product
    2NDC:0574-4024-3924 in 1 CARTON05/08/2014
    23.5 g in 1 TUBE; Type 0: Not a Combination Product
    3NDC:0574-4024-5050 in 1 CARTON05/08/2014
    31 g in 1 TUBE; Type 0: Not a Combination Product
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    ANDAANDA06244705/08/2014
    Labeler - Paddock Laboratories, LLC (967694121)